Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab +/- Radiotherapy in Recurrent/Metastatic Esophageal Cancer
NCT04512417Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2020
- Primary completion
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in esophageal cancer, sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT04512417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04512417.